{
    "info": {
        "nct_id": "NCT03220217",
        "official_title": "A Multicentre, Randomised, Dose-confirmation, Factorial Phase II Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)",
        "inclusion_criteria": "* Pathologically confirmed, well differentiated functioning or non-functioning metastatic GEP-NET (Grade I and II as per World Health Organisation classification 2010)\n* Confirmed presence of somatostatin receptors (type 2) on technically evaluable tumour lesions documented by a positive Somatostatin Receptor Scan acquired within 6 months prior to screening (Visit 1) and showing minimally two lesions in at least one of the key organs; these images shall be available to be sent to the imaging core lab electronically to ascertain quality and admissibility\n* Body weight between 50 kg (110 lb) and 110 kg (243 lb), inclusive\n* Adequate bone marrow, liver and renal function\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Fewer than five lesions in total and more than 25 lesions/organ detected by the previous somatostatin receptor scan in key organs: liver, lymph nodes, bone or lungs\n* Subject who have received treatment of any somatostatin analogue, including Somatuline® Autogel® /Depot®, Sandostatin® LAR within 28 days, and Sandostatin® within 24 hours prior to first 68Ga-OPS202 administration\n* Prior or planned administration of a radiopharmaceutical within 8 half-lives of the radionuclide\n* Any condition that precludes the proper performance of PET and/or CT scan: a) Subjects who are not able to tolerate the CT contrast agent, b) Subjects with metal implants or arthroplasty, or any other objects that might interfere with the PET and/or CT analysis, c) Subjects unable to raise arms for prolonged imaging purposes, d) Subjects unable to lie still for the entire imaging time, e) Subjects weighing greater than 110 kg (243 lb)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Adequate bone marrow, liver and renal function",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... liver",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Body weight between 50 kg (110 lb) and 110 kg (243 lb), inclusive",
            "criterions": [
                {
                    "exact_snippets": "Body weight between 50 kg (110 lb) and 110 kg (243 lb), inclusive",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 50,
                                        "unit": "kg"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 110,
                                        "unit": "kg"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed presence of somatostatin receptors (type 2) on technically evaluable tumour lesions documented by a positive Somatostatin Receptor Scan acquired within 6 months prior to screening (Visit 1) and showing minimally two lesions in at least one of the key organs; these images shall be available to be sent to the imaging core lab electronically to ascertain quality and admissibility",
            "criterions": [
                {
                    "exact_snippets": "Confirmed presence of somatostatin receptors (type 2) on technically evaluable tumour lesions",
                    "criterion": "somatostatin receptor type 2 expression on tumour lesions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented by a positive Somatostatin Receptor Scan acquired within 6 months prior to screening (Visit 1)",
                    "criterion": "Somatostatin Receptor Scan",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "acquisition time",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to screening"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "showing minimally two lesions in at least one of the key organs",
                    "criterion": "number of lesions in key organs",
                    "requirements": [
                        {
                            "requirement_type": "count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lesions in at least one key organ"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "these images shall be available to be sent to the imaging core lab electronically",
                    "criterion": "availability of imaging for core lab review",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "format",
                            "expected_value": "electronic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologically confirmed, well differentiated functioning or non-functioning metastatic GEP-NET (Grade I and II as per World Health Organisation classification 2010)",
            "criterions": [
                {
                    "exact_snippets": "Pathologically confirmed",
                    "criterion": "diagnosis confirmation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathological"
                        }
                    ]
                },
                {
                    "exact_snippets": "well differentiated",
                    "criterion": "tumor differentiation",
                    "requirements": [
                        {
                            "requirement_type": "differentiation",
                            "expected_value": "well differentiated"
                        }
                    ]
                },
                {
                    "exact_snippets": "functioning or non-functioning",
                    "criterion": "tumor functionality",
                    "requirements": [
                        {
                            "requirement_type": "functionality",
                            "expected_value": [
                                "functioning",
                                "non-functioning"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "metastatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "GEP-NET",
                    "criterion": "tumor type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "gastroenteropancreatic neuroendocrine tumor"
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade I and II as per World Health Organisation classification 2010",
                    "criterion": "tumor grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "Grade I",
                                "Grade II"
                            ]
                        },
                        {
                            "requirement_type": "grading system",
                            "expected_value": "World Health Organisation classification 2010"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any condition that precludes the proper performance of PET and/or CT scan: a) Subjects who are not able to tolerate the CT contrast agent, b) Subjects with metal implants or arthroplasty, or any other objects that might interfere with the PET and/or CT analysis, c) Subjects unable to raise arms for prolonged imaging purposes, d) Subjects unable to lie still for the entire imaging time, e) Subjects weighing greater than 110 kg (243 lb)",
            "criterions": [
                {
                    "exact_snippets": "not able to tolerate the CT contrast agent",
                    "criterion": "CT contrast agent tolerance",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "metal implants or arthroplasty, or any other objects that might interfere with the PET and/or CT analysis",
                    "criterion": "presence of metal implants or interfering objects",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to raise arms for prolonged imaging purposes",
                    "criterion": "ability to raise arms for prolonged imaging",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to lie still for the entire imaging time",
                    "criterion": "ability to lie still for entire imaging time",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "weighing greater than 110 kg (243 lb)",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 110,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fewer than five lesions in total and more than 25 lesions/organ detected by the previous somatostatin receptor scan in key organs: liver, lymph nodes, bone or lungs",
            "criterions": [
                {
                    "exact_snippets": "Fewer than five lesions in total",
                    "criterion": "total number of lesions",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "lesions"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "more than 25 lesions/organ detected by the previous somatostatin receptor scan in key organs: liver, lymph nodes, bone or lungs",
                    "criterion": "number of lesions per organ (liver, lymph nodes, bone, lungs) detected by somatostatin receptor scan",
                    "requirements": [
                        {
                            "requirement_type": "quantity per organ",
                            "expected_value": {
                                "operator": ">",
                                "value": 25,
                                "unit": "lesions/organ"
                            }
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": "somatostatin receptor scan"
                        },
                        {
                            "requirement_type": "organ",
                            "expected_value": [
                                "liver",
                                "lymph nodes",
                                "bone",
                                "lungs"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior or planned administration of a radiopharmaceutical within 8 half-lives of the radionuclide",
            "criterions": [
                {
                    "exact_snippets": "Prior or planned administration of a radiopharmaceutical within 8 half-lives of the radionuclide",
                    "criterion": "administration of a radiopharmaceutical",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to study",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "half-lives of the radionuclide"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject who have received treatment of any somatostatin analogue, including Somatuline® Autogel® /Depot®, Sandostatin® LAR within 28 days, and Sandostatin® within 24 hours prior to first 68Ga-OPS202 administration",
            "criterions": [
                {
                    "exact_snippets": "received treatment of any somatostatin analogue, including Somatuline® Autogel® /Depot®, Sandostatin® LAR within 28 days",
                    "criterion": "treatment with somatostatin analogue (Somatuline Autogel/Depot, Sandostatin LAR)",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "received treatment of ... Sandostatin® within 24 hours prior to first 68Ga-OPS202 administration",
                    "criterion": "treatment with Sandostatin",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}